Eloxx Pharmaceuticals (ELOX) Stock Price, News & Analysis

Company Overview

Eloxx Pharmaceuticals, Inc. was a clinical-stage biopharmaceutical company focused on developing treatments for rare genetic diseases caused by nonsense mutations. Its research centered on ribosome modulation therapy, an approach intended to encourage cells to read through certain genetic mutations and restore production of functional proteins.

The company’s lead investigational product was ELX-02, a synthetic aminoglycoside designed to promote readthrough of nonsense mutations while seeking to limit the toxicity associated with older aminoglycoside compounds. Eloxx studied ELX-02 in genetic disorders including cystinosis and explored its potential application in other diseases involving nonsense mutations.

Eloxx’s programs were directed primarily at rare-disease markets and were investigational rather than established commercial products. The company’s publicly reported operations and pipeline were subject to significant changes, and reliable current information about its leadership, corporate status, and active programs is limited.

Key Stats

• Today's Range: $12.60 to $13.31
• 50-Day Range: $12.21 to $18.53
• 52-Week Range: $8.20 to $23.40
• Volume: 19,617 shs
• Average Volume: 25,252 shs
• Market Capitalization: $51.47 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $37.33
• Consensus Rating: Moderate Buy

Eloxx Pharmaceuticals Stock Analysis - MarketRank™

Eloxx Pharmaceuticals scored higher than 78% of companies evaluated by MarketBeat, and ranked 113th out of 891 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Eloxx Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 2 strong buy ratings, 3 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Eloxx Pharmaceuticals has a consensus price target of $37.33, representing about 193.0% upside from its current price of $12.74.

Amount of Analyst Coverage

Eloxx Pharmaceuticals has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Eloxx Pharmaceuticals are expected to grow in the coming year, from ($2.61) to ($2.02) per share.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.38% of the float of Eloxx Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Eloxx Pharmaceuticals has a short interest ratio ("days to cover") of 1.78, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Eloxx Pharmaceuticals has recently decreased by 23.34%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Eloxx Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Eloxx Pharmaceuticals does not have a long track record of dividend growth.

News and Social Media

• Score: 1.9 / 5
• News Sentiment: -0.02

News Sentiment

Eloxx Pharmaceuticals has a news sentiment score of -0.02. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.40 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for Eloxx Pharmaceuticals this week, compared to 1 article on an average week.

Search Interest

2 people have searched for ELOX on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 0.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Eloxx Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

25.90% of the stock of Eloxx Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

2.90% of the stock of Eloxx Pharmaceuticals is held by institutions.

Company Calendar

• Last Earnings: 8/11/2026
• Today: 11/05/2026
• 3rd Annual Guggenheim Healthcare Innovation Conference: 11/09/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:ELOX
• CIK: 1035354
• Web: www.eloxxpharma.com
• Phone: 781-577-5300
• Fax: 908-864-4440
• Employees: 7
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Eloxx Pharmaceuticals: $37.33
• High Price Target: $40.00
• Low Price Target: $32.00
• Potential Upside/Downside: +193.0%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.86
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.74
• Quick Ratio: 3.74

Sales & Book Value

• Annual Sales: $6.36 million
• Price / Sales: 8.09
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($85.17) per share
• Price / Book: -0.15

Miscellaneous

• Outstanding Shares: 4,040,000
• Free Float: 2,991,000
• Market Cap: $51.47 million
• Optionable: N/A
• Beta: -1,918.69